Amphastar Asks Jury To Nix $1B Momenta Infringement Case

By Brian Amaral · July 20, 2017, 9:30 PM EDT

Amphastar Pharmaceuticals on Thursday told a federal jury in Boston that generic competitor Momenta's "outrageous" dishonesty in developing standards for a lucrative blood thinner should end the company's patent infringement case....

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

Momenta Pharmaceuticals, Inc. et al v. Amphastar Pharmaceuticals, Inc. et al

Case Number

1:11-cv-11681

Court

Massachusetts

Nature of Suit

Patent

Date Filed

September 21, 2011